Honored to present the results of POLCA GB Trial of neoadjuvant chemoradiation vs chemotherapy alone in borderline respectable Gall bladder cancers
Oral presentation at ASCO 2025 on 31st May
https://t.co/3qycIrjMFd
We acknowledge this publication by our surgical colleagues comparing RT techniques for impact on patient’s functional outcomes
We would like to caution readers regarding certain limitations which are already acknowledged in the paper 🚩🚩🚩
Thread >>> (1/6)
One week vs. 5 weeks has a much larger impact on both patient and care provider QoL and their pockets in addition to the superior DFS (7% RAPIDO)
These benefits outweigh short-term minor inconveniences (5/6)